U.S. markets closed

PAO Group, Inc. (PAOG)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0080+0.0002 (+1.91%)
At close: 3:58PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0078
Open0.0079
BidN/A x N/A
AskN/A x N/A
Day's Range0.0077 - 0.0080
52 Week Range0.0003 - 0.0200
Volume8,172,743
Avg. Volume40,691,610
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • PAOG Advances CBD Pharmaceutical Developments Backed By US Patent
    Newsfile

    PAOG Advances CBD Pharmaceutical Developments Backed By US Patent

    Sandusky, Ohio--(Newsfile Corp. - April 8, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced a management update on the company's ongoing CBD Pharmaceutical Development Program progress scheduled to be released next week on Tuesday, April 13, 2021.Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 ...

  • PAOG U.S. Patent Backed CBD Pharmaceutical Development Remains On Track
    PR Newswire

    PAOG U.S. Patent Backed CBD Pharmaceutical Development Remains On Track

    PAO Group, Inc. (USOTC: PAOG) today announced a management update on the company's ongoing CBD Pharmaceutical Development Program progress scheduled to be released next week on Tuesday, April 13, 2021.

  • PAOG Targets September 2021 to Introduce CBD Nutraceuticals to Market Co-Packed by ALKM and Marketed Through USMJ
    Newsfile

    PAOG Targets September 2021 to Introduce CBD Nutraceuticals to Market Co-Packed by ALKM and Marketed Through USMJ

    Sandusky, Ohio--(Newsfile Corp. - March 16, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today released details on the Company's nutraceutical developments initiative following last week's introduction of adding CBD RELAX-RX to existing CBD RespRx developments. The details today are highlighted by the Company's September 2021 go-to-market target date with nutraceutical co-packing to be conducted by Alkame Holdings, Inc. (OTC Pink: ALKM) and product marketing to be conducted by North American Cannabis ...